Verpasep caltespen

Drug Profile

Verpasep caltespen

Alternative Names: BCG65-E7; HspE7; Oncocine HspE7; R1461; SGN-00101

Latest Information Update: 18 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Developer Akela Pharma
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis

Highest Development Phases

  • Discontinued Anal dysplasia; Cervical cancer; Cervical dysplasia; Cervical intraepithelial neoplasia; Human papillomavirus infections; Recurrent respiratory papillomatosis

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 25 Feb 2013 Discontinued - Phase-I for Cervical intraepithelial neoplasia in USA (SC; new formulation)
  • 25 Feb 2013 Discontinued - Phase-II for Cervical cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top